Leukemia & Lymphoma
Leukemia & Lymphoma is an international peer-reviewed journal published by Taylor & Francis, covering all aspects of hematological malignancies. Founded in 1989, it has a 2025 impact factor of 2.1 and is indexed in SCIE.《白血病与淋巴瘤》（Leukemia & Lymphoma）是由 Taylor & Francis 出版的国际性同行评审期刊，涵盖血液系统恶性肿瘤的各个方面。该刊创刊于 1989 年，2025 年影响因子为 2.1，被 SCIE 收录。
Scope
The journal's stated aim is to publish research on all aspects of hematological malignancies, addressing the needs of physicians and scientists interested in clinical, translational, laboratory, and basic science research, with its official scope covering:刊物官方宗旨为发表血液系统恶性肿瘤各方面的研究，满足对临床、转化、实验室与基础科学研究感兴趣的医师与科学家的需求，官方声明的征稿范围包括：
- Disease biology: research on the biology of hematological malignancies, including the molecular and cellular mechanisms underlying leukemia and lymphoma.疾病生物学： 关于血液系统恶性肿瘤生物学的研究，涵盖白血病与淋巴瘤的分子与细胞机制等。
- Clinical and translational research: studies on clinical and clinico-pathological investigations, including diagnosis, treatment, and outcomes of patients with malignant hematological disorders.临床与转化研究： 关于临床与临床病理学研究，涵盖恶性血液病患者的诊断、治疗与结局等。
- Novel agents and pharmacology: work on novel therapeutic agents, chemotherapy, pharmacology, and pharmacogenomics in hematological malignancies.新药与药理学： 关于血液系统恶性肿瘤的新型治疗药物、化疗、药理学与药物基因组学研究。
- Epidemiology and ethics: research on the epidemiology, ethics, and public health aspects of hematological malignancies.流行病学与伦理学： 关于血液系统恶性肿瘤的流行病学、伦理学与公共卫生方面的研究。
- Article types: original research articles, review articles, and letters to the editor, covering both clinical and fundamental research in hematological oncology.栏目设置： 接受原创研究论文、综述与读者来信，涵盖血液肿瘤学的临床与基础研究。
History
- Founding: Leukemia & Lymphoma was founded in 1989 as an international journal covering both clinical and basic aspects of hematologic malignancies.创刊： 《白血病与淋巴瘤》创刊于 1989 年，是一份涵盖血液系统恶性肿瘤临床与基础方面的国际期刊。
- Publisher evolution: the journal was originally published by Informa Healthcare, and is now published by Taylor & Francis following the integration of Informa's academic publishing business into the Taylor & Francis Group.出版方沿革： 该刊最初由 Informa Healthcare 出版，后因 Informa 学术出版业务并入 Taylor & Francis 集团，现由 Taylor & Francis 出版。
- Editorial leadership: the journal is led by joint editors-in-chief, with Aaron Polliack, Koen Van Besien, and John Seymour serving in this role.编辑领导： 该刊由联合主编领导，现任联合主编为阿龙·波利亚克（Aaron Polliack）、科恩·范贝西安（Koen Van Besien）与约翰·西摩（John Seymour）。
- International reach: the journal has grown into an internationally recognised journal in hematology and oncology, with contributions from researchers and clinicians worldwide.国际影响力： 该刊已发展为血液学与肿瘤学领域的国际知名期刊，汇聚全球研究人员与临床医生的投稿。
Editors
The journal is led by joint editors-in-chief supported by an international editorial board:该刊由联合主编领导，国际编委会协助工作：
- Joint editors-in-chief: Aaron Polliack, Koen Van Besien of the University of Chicago Medical Center, and John Seymour of the Peter MacCallum Cancer Centre in Melbourne, Australia, serve as joint editors-in-chief.联合主编： 阿龙·波利亚克（Aaron Polliack）、芝加哥大学医学中心的科恩·范贝西安（Koen Van Besien）与澳大利亚墨尔本彼得·麦卡勒姆癌症中心的约翰·西摩（John Seymour）担任联合主编。
- Editorial board: the journal has an international editorial board comprising hematologists and oncologists from leading institutions worldwide.编委会： 该刊拥有国际编委会，成员来自全球顶尖机构的血液学家与肿瘤学家。
- Review model: manuscripts undergo peer review by external experts in hematology and oncology, with editorial decisions based on scientific quality, novelty, and clinical significance.评审模式： 稿件由血液学与肿瘤学领域外部专家进行同行评审，编辑决定基于科学质量、新颖性与临床意义做出。
- Publication model: the journal is published monthly, with a hybrid open access model allowing authors to choose between subscription and open access publication.出版模式： 该刊每月出版，采用混合开放获取模式，作者可选择订阅模式或开放获取模式发表。